Pharmacovigilance in the EAEU and CIS in 2026: MAH Requirements

Updated 15 July 2026. Pharmacovigilance in the Eurasian Economic Union (EAEU) and the wider CIS region is not one uniform regulatory system. The EAEU establishes supranational rules for Armenia, Belarus, Kazakhstan, Kyrgyzstan and Russia. The CIS is a broader intergovernmental framework but does not create one mandatory pharmacovigilance regime for all participants. Azerbaijan, Georgia, Uzbekistan, Tajikistan, Turkmenistan and Ukraine apply their own national requirements.

For a marketing authorisation holder (MAH), this creates a two-level compliance model: applicable EAEU requirements for Union authorisations plus the national obligations of every country in which the medicine is marketed.

EAEU versus CIS: the regulatory distinction

The EAEU is an international organisation for regional economic integration. In the medicines sector, its Member States develop a common market through acts of the Eurasian Economic Commission (EEC). Union pharmacovigilance requirements form part of EAEU law.

The CIS does not impose an equivalent common GVP system. “CIS pharmacovigilance” is therefore a practical regional description covering markets with related regulatory histories but different competent authorities, reporting timelines, local-person requirements, submission channels and language rules.

Core EAEU pharmacovigilance framework

• EEC Council Decision No. 87 of 3 November 2016 establishes the EAEU Good Pharmacovigilance Practice Rules.
• 2025 amendments updated EAEU GVP and should be reflected in procedures, the pharmacovigilance system master file, signal management, risk-management planning and related processes.
• EAEU registration and assessment rules govern Union authorisations, dossier alignment and post-authorisation variations.
• Common approaches to pharmacovigilance inspections reinforce the need for continuous inspection readiness rather than preparation only after notification.

From 1 January 2026, the EAEU common medicines market moved to circulation under Union registration rules. For legacy products, transitional provisions and the actual dossier status must be assessed for each product and Member State. MAHs should maintain documented evidence of the regulatory status of every authorisation rather than relying on a general description of the transition.

Key MAH responsibilities under the EAEU system

1. Pharmacovigilance system and QPPV

The MAH must maintain an effective pharmacovigilance system and appoint a qualified person with appropriate competence, authority and access to safety information. National law or the company operating model may additionally require local pharmacovigilance contacts.

2. Pharmacovigilance system master file

The PSMF must accurately describe the operating system: governance, data sources, safety databases, contracts, processes, quality metrics, training, audits and document control. A gap between the PSMF and actual practice is a significant inspection risk.

3. Individual case safety reports

The system should support intake, validation, medical assessment, coding, duplicate detection, follow-up and timely submission of suspected adverse reactions. Sources include spontaneous reports, medical literature, patient-support programmes, studies, digital channels and partner data.

4. Signal management

MAHs need documented detection, validation, confirmation, analysis, prioritisation and closure of safety signals. Decisions should be traceable and linked to product-information changes, the risk-management plan and risk-minimisation measures where relevant.

5. PSURs and benefit–risk evaluation

Periodic safety reports must follow the applicable schedule and integrate cumulative data, signals, new risks, effectiveness of risk minimisation and the current benefit–risk evaluation. The required schedule and format should be confirmed for each authorisation.

6. Risk-management plan

The RMP should reflect identified and potential risks, missing information, routine and additional pharmacovigilance activities, and risk-minimisation measures. Changes in the safety profile require timely assessment of whether the RMP should be updated.

7. Safety agreements and partner oversight

Safety Data Exchange Agreements should define reportable sources, transfer timelines, case ownership, reconciliation, signal exchange, literature duties, regulatory requests and change control. Outsourcing a task does not transfer the MAH’s ultimate responsibility.

Inspection readiness in 2026

1. Update the PSMF and annexes after organisational and regulatory changes.
2. Map SOPs against the current EAEU GVP requirements.
3. Confirm training for the QPPV, local contacts and relevant functions.
4. Reconcile partner data and resolve overdue cases.
5. Verify computerised-system validation, access control and audit trails.
6. Review quality metrics, deviations and CAPAs.
7. Perform an internal audit or mock inspection of critical processes.
8. Maintain a product-by-country register of EAEU and national authorisation status.

Markets outside the EAEU

Azerbaijan, Georgia, Uzbekistan, Tajikistan, Turkmenistan and Ukraine are not EAEU Member States. National rules determine case-reporting timelines, local responsible-person requirements, PSURs, RMPs, local literature, language and submission channels. A system aligned with EAEU GVP or EU GVP does not remove local obligations.

PharmExpert supports MAHs in Armenia, Belarus, Kazakhstan, Kyrgyzstan, Russia and other regional markets with QPPV and local contact services, PSMFs, literature and regulatory monitoring, case management, signal management, PSURs, RMPs, audits, inspection readiness and safety agreements.

Conclusion

In 2026, effective EAEU and CIS pharmacovigilance requires a controlled matrix of Union and national requirements rather than one regional template. Priorities for MAHs are verified authorisation status, a current GVP system, local accountability, documented safety-data exchange and continuous inspection readiness.

Official sources

1. EEC: acts in the sphere of circulation of medicinal products.
2. EEC: Russian-language medicines legislation portal.
3. EEC: Concept for Developing the Common Market of Medicines, 15 August 2025.

This article provides general information. Before making a regulatory decision, verify the current EAEU acts and the national law of the relevant country.